Erste Group downgraded Eli Lilly from Buy to Hold
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/5/2025 | Buy → Hold | Erste Group | |
| 4/28/2025 | $1150.00 → $700.00 | Buy → Reduce | HSBC Securities |
| 4/22/2025 | $975.00 | Overweight | Cantor Fitzgerald |
| 12/10/2024 | $997.00 | Buy | BofA Securities |
| 11/15/2024 | $1000.00 | Outperform | Wolfe Research |
| 10/17/2024 | $1100.00 | Outperform | Bernstein |
| 9/13/2024 | $1060.00 | Buy | Citigroup |
| 8/12/2024 | $1025.00 | Hold → Buy | Deutsche Bank |
Erste Group downgraded Eli Lilly from Buy to Hold
HSBC Securities downgraded Eli Lilly from Buy to Reduce and set a new price target of $700.00 from $1,150.00 previously
Cantor Fitzgerald initiated coverage of Eli Lilly with a rating of Overweight and set a new price target of $975.00
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
Asha Therapeutics (Asha), a life sciences company pioneering breakthrough therapeutics for neurological disease, announced today the company has been awarded a grant from the ALS Association through its Lawrence and Isabel Barnett Drug Development Program for the advancement of ASHA-624, a novel brain-penetrant intra-molecular glue inhibitor of SARM1. The grant will support the continued development of ASHA-624 towards first-in-human clinical trials as a potential disease-modifying therapeutic for Amyotrophic Lateral Sclerosis (ALS). ASHA-624 was designed using Asha's proprietary PRISM™ drug design technology, which creates new medicines to restore normal biology and provide functional cu
INDIANAPOLIS, Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's Executive Committee, effective immediately. Since joining Lilly in 2001, Montarce has held a range of finance leadership roles, including serving as group vice president, corporate controller and chief financial officer of Lilly Research Laboratories; vice president, finance and chief financial officer of Lilly International; and vice president, finance and global chief financial officer of Elanco Health. He most recently served in the role of Lilly president and general manage
INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that Marschall S. Runge, M.D., Ph.D. is retiring from his role as an independent director of Lilly's board of directors effective Aug. 31, 2024. Dr. Runge has served on Lilly's board since 2013, including as a member of the board's Science and Technology Committee and Ethics and Compliance Committee. He is currently the CEO of Michigan Medicine, executive vice president for medical affairs at the University of Michigan and dean of the Medical School, and he plans to retire on June 30, 2025. Following retirement from these leadership roles, Dr. Runge will remain on the Medical School faculty as a prof
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
SD - ELI LILLY & Co (0000059478) (Filer)
8-K - ELI LILLY & Co (0000059478) (Filer)
10-Q - ELI LILLY & Co (0000059478) (Filer)
INDIANAPOLIS, June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 46th Annual Global Health Care Conference on June 10, 2025. Lucas Montarce, Lilly executive vice president and chief financial officer, will take part in a fireside chat at 8 a.m., Eastern time. A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for approximately 90 days. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been p
INDIANAPOLIS, June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156) demonstrated an encouraging safety profile and anti-tumor activity across dose and FRα expression levels in women with heavily pre-treated platinum-resistant ovarian cancer, including patients previously treated with mirvetuximab soravtansine. A preliminary overall objective response rate (ORR) of 55% was observed at the potential recommended Phase 2 dose of 4 mg/kg. Lilly's FRα targeting ADC is composed of an Fc-silent, FRα specific humanized monoclonal antibody linked to exatecan, a topoisomerase
INDIANAPOLIS, May 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at the American Diabetes Association's (ADA) 85th Scientific Sessions taking place June 20-23 in Chicago. Lilly will also host an investor event to highlight the company's cardiometabolic health portfolio and discuss key presentations from the ADA Scientific Sessions. The event will be held on Sunday, June 22 at 6:30 p.m. CDT and will be accessible via a live webcast on the "Webcasts & Presentations" section of Lilly's investor website. A repla
For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa
For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ
For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat
INDIANAPOLIS, May 5, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the second quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on June 10, 2025, to shareholders of record at the close of business on May 16, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries
Revenue in Q1 2025 increased 45% to $12.73 billion driven by volume growth from Mounjaro and Zepbound. Pipeline progress included positive Phase 3 trial results for orforglipron (small molecule oral GLP-1 agonist) in Type 2 diabetes in the first of seven obesity and diabetes Phase 3 trials.Q1 2025 EPS increased 23% to $3.06 on a reported basis and increased 29% to $3.34 on a non-GAAP basis, both inclusive of $1.72 of acquired IPR&D charges.Revenue guidance reaffirmed to be between $58.0 billion and $61.0 billion. INDIANAPOLIS, May 1, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025. "Lilly had a solid start to the year
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to